undamentalytics Newsletter
Sign in

Abvc Biopharma, Inc. balance sheet

At the end of fiscal 2025, Abvc Biopharma, Inc. had total assets of $21.1m, total liabilities of $7.8m and shareholders' equity of $11.1m. It held $681,480 in cash against $755,512 of debt: net debt of $74,032.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Sept 20102011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Dec 20152018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents—————000460001
Receivables——000———0000——
Inventory———0000——0————
Total current assets00000011683223
Total assets000000671214108821
Accounts payable10—————00—————
Deferred revenue (current)——————————0000
Total current liabilities32220—117546676
Short-term debt——————12222111
Long-term debt————————3—————
Total debt1000—013442321
Total liabilities————0—117956778
Shareholders' equity−3−1−2−200−6−03932111
Non-controlling interests and other (assets − liabilities − equity)——————0—−1——−0−12
Net debt (negative = net cash)—————−013−0−22320
Shares outstanding—71m71m57m—65m————3m—14m25m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABVC vs CRDFABVC vs CRVOABVC vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abvc Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abvc Biopharma, Inc.